Related Experiment Video
Updated: Aug 10, 2026
Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
Published on: June 4, 2017
Effect of MX2, a new morpholino anthracycline, against experimental brain tumors
S Izumoto1, N Arita, T Hayakawa
1Department of Neurosurgery, Osaka University Medical School, Japan.
Abstract:
A new lipophilic morpholino anthracycline derivative, MX2, has an antitumor activity against a wide spectrum of experimental tumors. We examined the effect of MX2 against experimental brain tumors. At a low dose, MX2 exhibited strong growth inhibitory activity against human and rat glioma cells. The survival time of rats with meningeal carcinomatosis induced by intracisternal inoculation of Walker 256 carcinosarcoma cells was significantly prolonged by intravenous MX2. The growth of subcutaneously implanted glioma in rats was significantly retarded by intravenous MX2. These results suggest that MX2 warrants further experimental evaluation of its efficacy against malignant brain tumors including gliomas.
Insights
A novel drug, MX2, shows significant promise in treating experimental brain tumors, including gliomas. This lipophilic morpholino anthracycline derivative effectively inhibits tumor growth and prolongs survival in preclinical models.
Area of Science:
- Oncology
- Pharmacology
- Neuro-oncology
Background:
- Morpholino anthracycline derivatives represent a class of compounds with demonstrated antitumor activity.
- Malignant brain tumors, such as gliomas, pose significant therapeutic challenges due to their aggressive nature and limited treatment options.
Purpose of the Study:
- To evaluate the efficacy of MX2, a novel lipophilic morpholino anthracycline derivative, against experimental brain tumors.
- To assess the growth inhibitory and survival-modulating effects of MX2 in preclinical models of glioma and meningeal carcinomatosis.
Main Methods:
- In vitro assessment of MX2's effect on human and rat glioma cell proliferation.
- In vivo studies involving intravenous administration of MX2 in rats with intracisternally inoculated Walker 256 carcinosarcoma (meningeal carcinomatosis) and subcutaneously implanted gliomas.
Main Results:
- MX2 demonstrated potent growth inhibitory activity against both human and rat glioma cells at low doses.
- Intravenous administration of MX2 significantly prolonged the survival time of rats with meningeal carcinomatosis.
- Subcutaneous glioma growth in rats was significantly retarded following intravenous MX2 treatment.
Conclusions:
- MX2 exhibits significant preclinical efficacy against experimental brain tumors, including gliomas.
- The findings support further investigation of MX2 as a potential therapeutic agent for malignant brain tumors.
- MX2 warrants advanced experimental evaluation for its potential in treating gliomas and other brain malignancies.
